Colon, lung, and liver cancers are among the most prevalent and lethal cancers globally. Despite advancements in treatment, these cancers continue to pose significant challenges due to high mortality ...

A panelist discusses how multiple molecular biomarkers beyond BRCA and homologous recombination deficiency (HRD) testing are emerging as important for guiding ovarian cancer therapy, including ...

A key molecular dynamic could be the key to fighting tumors while allowing patients to still receive life-saving cell ...

Treatments based on genomic profiling can significantly extend survival for patients with advanced or rare cancer, but only ...

Wistar scientists have combined a promising cancer therapy with a molecule that targets tumors to treat cancer more effectively. The new approach could be a way to deliver treatment directly to tumors ...

Daraxonrasib, a new pancreatic cancer drug, cut the risk of death by 60% in a Phase 3 trial. A doctor explains how it works, side effects and when it could reach patients.

A peptide that successfully targeted and killed metastatic cancer cells in mice may open the door to developing more ...

Aging and cancer are deeply intertwined: advancing age is the single largest risk factor for most malignancies, and many of the molecular processes that ...

Erasca Inc. (NASDAQ:ERAS) is a California-based clinical-stage precision oncology company that provides solutions for ...

Panelists conflicted about positive trial's ability to validate biomarker-guided switching ...